Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03737643
Title Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients. (DUO-O)
Recruitment Recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca

fallopian tube cancer

peritoneum cancer

ovary serous adenocarcinoma

endometrioid ovary carcinoma

ovarian clear cell carcinoma

ovarian carcinosarcoma


Bevacizumab + Carboplatin + Paclitaxel

Bevacizumab + Carboplatin + Durvalumab + Paclitaxel

Bevacizumab + Durvalumab + Olaparib


Bevacizumab + Durvalumab

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT

No variant requirements are available.